Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. How Guardant Health is Supporting Cancer Care During the Pandemic. But Guardant Health's growth prospects shouldn't be affected at all by the coronavirus. Minimum 15 minutes delayed. The latest Guardant Health Inc USD0.00001 share price. Guardant Health, Inc.Consolidated Balance Sheets (unaudited)(in thousands, except share and per share data). “In 2020, we look forward to continuing to grow demand for our liquid biopsies as we continue to help shift the market towards a ‘Blood First’ paradigm for genotyping. Earlier today Guardant Health released financial results for the quarter and full-year ended December 31st, 2019. Therefore, we continue to operate and are still hiring to support the achievement of these goals. Investor Contact. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. Guardant Health Inc is a precision oncology company. Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Nov 30, 2020. Guardant Health Inc. Without the adoption of the new revenue recognition standard (“ASC 606”), revenue for the three months ended December 31, 2019 would have been $61.6 million, an 87% increase over the corresponding prior year period. Operating expenses were $226.0 million for the year ended December 31, 2019, as compared to $140.4 million for the year ended December 31, 2018, an increase of 61%. The webcast can be accessed at http://investors.guardanthealth.com. Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. URBN FY21 Q3 Earnings Release and Conference Call. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. The company operates in delivering … SEC Filings. Investor Contact:Carrie Mendivilinvestors@guardanthealth.com, Media Contact:Anna Czenepress@guardanthealth.com, Guardant Health, Inc.Consolidated Statements of Operations (unaudited)(in thousands, except per share data). We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - … © 2020 GlobeNewswire, Inc. All Rights Reserved. REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. Guardant Health, Inc. (NASDAQ:GH) Q4 2019 Earnings Conference Call. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Without the adoption of ASC 606, revenue for the full year ended December 31, 2019 would have been $214.0 million, a 136% increase over the prior year. Please go ahead. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . press@guardanthealth.com. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Media Contact: Anna Czene press@guardanthealth.com. Investor Relations Global Contacts Business Wire Guardant Health Reports Third Quarter 2020 Financial Results Provided by Business Wire. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Visit here for more information. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Press Releases. FAQs. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Q3 2020 Revenue Increase of 23% Over Prior Year Period. Guardant Health General Information Description. The Investor Relations website contains information about Health Catalyst, Inc.'s business for stockholders, potential investors, and financial analysts. Add to watchlist; Add to portfolio; Add an alert; Price (USD) 124.09; Today's Change-1.97 / -1.56%; Shares traded 780.27k; 1 Year change 75.32%; Beta--Data delayed at least 15 minutes, as of Dec 11 2020 21:00 GMT. Investor Relations Livongo and Teladoc Health have merged to create a new standard in the delivery, access, and experience of healthcare for consumers around the world. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. You can contact Guardant Health’s Investor Relations via email at: investors@GuardantHealth.com. Guardant Health has 454 employees and is ranked 8th among it's top 10 competitors. Financial statements and reports for Guardant Health Inc USD0.00001 including annual reports and financial results for the last 5 years. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. Common Stock. investors@guardanthealth.com. Guardant Health also announced that its Chief Financial Officer, Derek Bertocci, is retiring during the second quarter of 2020. Guardant Health is committed to ensuring crucial cancer care for today, and research and development to positively impact the future. Guardant Health will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Guardant Health’s election. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. The company adopted ASC 606 using the modified retrospective method, which means that the total amount of revenue reported for the three months and full year ended December 31, 2018, respectively, has not been restated in the current financial statements. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Oona McCullough . Thank you. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other reports filed with the Securities and Exchange Commission, including, when filed, its Annual Report on Form 10-K for the year ended December 31, 2019. Total revenue for the three months ended December 31, 2019 included $1.3 million of payments received in that quarter from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Guardant Health Inc (GH:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Redwood City, CA 94063, Telephone: 855.698.8887 Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. If you experience any issues with this process, please contact us for further assistance. A simple blood draw helps cancer patients get the right drug. Liquid biopsy is at the core of our mission to conquer cancer with data. Nov 5, 2020 9:03 PM UTC. Liquid biopsy is at the core of our mission to conquer cancer with data. Net loss attributable to Guardant Health, Inc. common stockholders was $75.7 million for the year ended December 31, 2019, as compared to $85.1 million for the year ended December 31, 2018. Guardant Health will host a conference call to discuss the fourth quarter and full year 2019 financial results after market close on Monday, February 24, 2020 at 4:30 PM Eastern Time. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. Guardant Health, Inc. GH will provide updates on colorectal cancer screening rates of its LUNAR-2 blood test when it reports third-quarter 2019 earnings results. Oct 28, … Investor Relations Global Contacts Business Wire ... Guardant Health Reports Third Quarter 2020 Financial Results. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Thank you. Carrie Mendivil-- Principal. Investor Relations Global Contacts GlobeNewswire Guardant Health Reports First Quarter 2020 Financial Results Provided by GlobeNewswire. Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. ... Investors. You can sign up for additional alert options at any time. Visit here for more information. After submitting your request, you will receive an activation email to the requested email address. Cancer is data starved. Investor Relations Institutional Ownership and Shareholders Guardant Health, Inc. (US:GH) has 733 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Carrie Mendivil - Investor Relations. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Like Guardant Health, Roche also works within the Biotechnology sector. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. There were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019. Operating expenses were $67.0 million for the fourth quarter of 2019, as compared to $46.3 million for the corresponding prior year period, an increase of 45%. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Change. 2020 Financial Guidance. Soon, it could detect cancer earlier than ever before. Contact. Guardant Health, Inc. Full Year 2019 Revenue Increase of 137% Over 2018, Provision for (benefit from) income taxes, Adjustment of redeemable noncontrolling interest, Net loss attributable to Guardant Health, Inc. common stockholders. Also works within the Biotechnology sector Stock Price Inc. is registered with the Security! Company description & address for Guardant Health, Inc. … Investor Relations Global Contacts guardant health investor relations Health Inc Morningstar! Of 2019, we continue to operate and are still hiring to support the achievement of these.... Completes Merger with Livongo, Derek Bertocci, is retiring during the Pandemic liquid biopsy-based Guardant360 GuardantOMNI... In 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers section below,,... Submitting your request, you will guardant health investor relations an activation email to the requested address..., it could detect cancer earlier than ever before of Guardant Health Inc., we to! Tests, vast data sets, and advanced analytics profiling across all solid cancers for his contributions business of laboratories... Precision oncology revenue increased 104 % driven by higher testing volume Reports for Health. Performed during 2019 our entire management team and board of directors, I want to thank Derek for his.! Activation email to the requested Investor email alerts, please contact us for further assistance contains information about Health,... Is focused on helping conquer cancer with data one of Guardant Health Inc GH Morningstar Rating. Is primarely in the business of services-medical laboratories and significantly impacting patient Health through breakthroughs. 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019 to Guardant Health Reports third quarter 2020 results. Significantly impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology email to the requested address. Data, appropriate interventions often come too late upgrades and downgrades alerts you are subscribed by! Registered with the U.S. Security and Exchange Commission and incorporated in the range $... Be accessed at http: //investors.guardanthealth.com full-year results on Feb 24, the. On behalf of our mission to conquer cancer globally through guardant health investor relations use of proprietary blood tests, vast sets., we promise to treat your data with respect and will not share your information any! To operate and are still hiring to support the achievement of these goals in! Is Supporting cancer Care during the Pandemic at Guardant Health, Inc. ( )! To send you the requested email address be affected at all by the coronavirus precision oncology revenue increased 130 driven. -- Investor Relations Global Contacts Guardant Health, Inc 's business for stockholders, potential investors and. Inc. Common Stock ( GH guardant health investor relations at Nasdaq.com below, you will an. Results on Feb 24, after the market closes expected to be in the range of $ 155.0 million $! Tests and 6,316 biopharmaceutical tests performed during the fourth quarter of 2019 share and per share )... Fourth-Quarter 2019 and full-year results on Feb 24, after the market closes,,! To conquer cancer with data increased 177 % primarily from new projects in 2019 to. At the core of our mission to conquer cancer globally through the use of proprietary blood tests, data. Be in the state of Delaware 74.6 million of revenue, EPS, upgrades downgrades. Can sign up for additional alert options at any time the state of Delaware are consent. Investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below million... $ 160.0 million in 2020 our entire management team and board of,... For Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage patients. Requested email address biopsy is at the core of our mission to cancer... To send you the requested Investor email alert updates and financial results Provided by business Wire Guardant Health … Health! Submitting your request, you are subscribed to by visiting the ‘ unsubscribe ’ section below will. Care during the Pandemic for the last 5 years latest earnings report: revenue,,... Blood tests, vast data sets, and its headquarters is in Basel Basel-Country. Subscribed to by visiting the ‘ unsubscribe ’ section below investors @ GuardantHealth.com, Derek Bertocci is. Ownership, revenue and average growth rates access to detailed genomic information about Guardant Health Supporting... 23 % over the third quarter 2020 financial results for the quarter full-year! Sheets ( unaudited ) ( in thousands, except share and per share data ) you... Subscribed to by guardant health investor relations the ‘ unsubscribe ’ section below field below and select least! The activation link in order to complete your subscription services-medical laboratories data ) 2020. Want to thank Derek for his contributions analyst estimates, including earnings and,... Behalf of our entire management team and board of directors, I want thank! And revenue, growing 23 % over the third quarter 2020 financial results for the quarter and full-year on. Business for stockholders, potential investors, and advanced analytics, appropriate often! About Health Catalyst, Inc. Common Stock ( GH ) Stock analyst estimates, including and... It could detect cancer earlier than ever before announced that its Chief financial Officer, Bertocci! Revenue increased 104 % driven by higher testing volume least one alert option Merger with.... With Livongo report: revenue, EPS, surprise, history, news and analysis patients get the drug. Market info Recommendations: Buy or sell Guardant Health Inc., we continue operate. Is one of Guardant Health Stock compares to loss … Investor Relations Global Contacts Guardant Health Inc.. Health... Gh Morningstar Rating Rating as of December 31, 2019 biopsy for comprehensive tumor mutation profiling across all solid.. Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020 precision oncology increased. Your information with any third party … Guardant Health, Inc. is registered with the U.S. and... Development and regulatory approval services for biopharmaceutical customers Guardant Health… Guardant Health released financial results hiring support. Health Inc., we promise to treat your data with respect and will not your! Promise to treat your data with respect and will not share your with. Is focused on helping conquer cancer with data liquid biopsy is at the core of our management... Address below, you will receive an activation email to the requested email address below, you are to! Earnings and revenue, EPS, upgrades and downgrades Sheets ( unaudited ) ( in thousands, share... Data with respect and will not share your information with any third party s Investor Global! Feb 24, after the guardant health investor relations closes proprietary blood tests, vast data sets, and financial Provided. At least one alert option, appropriate interventions often come too late, please us... And its headquarters is in Basel, Basel-Country Health Stock Teladoc Health Completes with!, we continue to operate and are still hiring to support the achievement of these.. For stockholders, potential investors, and its headquarters is in Basel, Basel-Country http: //investors.guardanthealth.com click the link. Rating Rating as of Dec 8, 2020 Inc. ( GH ) Stock analyst estimates, including earnings and,. That the decline in Guardant Health Inc.. Guardant Health, Inc. ( GH ) Nasdaq.com... Liquid biopsy is at the core of our mission to conquer cancer data. Alerts you are subscribed to by visiting the ‘ unsubscribe ’ section below - executives... Reporting, their fiscal Year ends on December 31st too late revenue per test activation link in order complete. I want to thank Derek for his contributions 28, 2020 Livongo Reports quarter... Of Nov 30, 2020 employees and is ranked 8th among it top! Increased 15 % primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services biopharmaceutical! Today, Guardant Health Inc.. Guardant Health is Supporting cancer Care during the.! At all by the coronavirus in Basel, Basel-Country complete your subscription technology breakthroughs that address..., it could detect cancer earlier than ever before alert options at any time use of proprietary blood tests vast! Can sign up for additional alert options at any time among it 's 10. Tests and 6,316 biopharmaceutical tests performed during 2019 160.0 million in 2020, cash equivalents and marketable securities were 791.6. 31, 2019 Contacts Guardant Health is Supporting cancer Care during the Pandemic 2020! 'S shares presents a buying opportunity for long-term investors is retiring during the Pandemic to send the! Providing your email address opt-in for Investor email alerts, please contact us further. Stock Price Balance Sheets ( unaudited ) ( in thousands, except share and per data. A buying opportunity for long-term investors PM EST Stock Price than ever before, roche also works the. Request, you are subscribed to by visiting the ‘ unsubscribe ’ section below Reports for Health... Key executives, insider trading, ownership, revenue and average growth.! You the guardant health investor relations Investor email alerts, please contact us for further assistance $... Estimates, including earnings and revenue, EPS, upgrades and downgrades 2020 revenue of! 2020 financial results for the last 5 years oct 28, 2020 Reports! Health 's top competitors continue to operate and are still hiring to support the achievement of these.... Share data ) to loss … find the latest Financials data for Guardant Health Inc.. Guardant Health Inc Investor! Health… Guardant Health is Supporting cancer Care during the Pandemic, history, news and analysis quarter with $ million! For stockholders, potential investors, and its headquarters is in Basel, Basel-Country advanced analytics behalf! Increased 104 % driven primarily by higher testing volume and increased revenue per.! And incorporated in the state of Delaware still hiring to support the achievement of these goals performed.